Brief: G1 Therapeutics Completes Enrollment In Phase 3 Clinical Trial Of Trilaciclib
10/10/2022 12:38
Oct 10 (Reuters) - G1 Therapeutics Inc GTHX.O :
* G1 THERAPEUTICS COMPLETES ENROLLMENT IN GLOBAL
MULTI-CENTER
PHASE 3 CLINICAL TRIAL OF TRILACICLIB IN PATIENTS WITH
METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC)
Source text for Eikon: ID:nGNX5XKnWH
Further company coverage: GTHX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on G1 Therapeutics
See all newsG1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Ralph Lauren, Illumina, Disney
U.S. STOCKS ON THE MOVE-Walt Disney, SpringWorks, Shopify